Cell Signaling Technology

Product Pathways - Neuroscience

Stargazin Antibody #2503

Applications Reactivity Sensitivity MW (kDa) Source
W H M R Endogenous 40 Rabbit

Applications Key:  W=Western Blotting
Reactivity Key:  H=Human  M=Mouse  R=Rat
Species cross-reactivity is determined by western blot. Species enclosed in parentheses are predicted to react based on 100% sequence homology.

Protocols

Specificity / Sensitivity

Stargazin Antibody detects endogenous levels of total stargazin protein.

Source / Purification

Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues of human stargazin. Antibodies are purified by protein A and peptide affinity chromatography.

Western Blotting

Western Blotting

Western blot analysis of extracts from A431, CAD and PC12 cells using Stargazin Antibody.

Background

Stargazin is a four-pass transmembrane protein related to VDCC (voltage dependent calcium channel) γ subunits and part of the TARP (transmembrane AMPA receptor regulatory protein) family of proteins. TARP proteins can form a complex with AMPA receptors (GluR1-4) and serve as integral auxiliary subunits (1-6).Interactions between stargazin and AMPA receptors are implicated in regulation of receptor surface expression, synaptic clustering and recycling, as well as increased receptor responsiveness to glutamate (1,2,5,6). Stargazin may play a role in the molecular mechanism of AMPAR-mediated inflammatory pain by taking part in signaling pathways that relay pain in the spinal cord (5). Because the protein also modulates the pharmacology of AMPA receptors, it enhances the effects of AMPAR potentiators that have therapeutic potential for a number of mental and neurodegenerative diseases (6).The carboxy terminus of the stargazin protein interacts with the PDZ domains of PSD95 and other membrane-associated guanylate kinase (MAGUK) family members, and together traffic AMPA receptors to the cell surface membrane, anchoring them to the postsynaptic site (1,7). Phosphorylation of stargazin by PKA on Thr321 inhibits this binding (3).

  1. Tomita, S. et al. (2005) Nature 435, 1052-1058.
  2. Priel, A. et al. (2005) J. Neurosci. 25, 2682-2686.
  3. Choi, J. et al. (2002) J. Biol. Chem. 277, 12359-12363.
  4. Osten, P. and Stern-Bach, Y. (2006) Curr. Opin. Neurobiol. 16, 275-280.
  5. Tao, F. et al. (2006) J. Neurosci. Res. 84, 867-873.
  6. Tomita, S. et al. (2006) Proc. Natl. Acad. Sci. USA 103, 10064-10067.
  7. Schnell, E. et al. (2002) Proc. Natl. Acad. Sci. USA 99, 13902-13907.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

For Research Use Only. Not For Use In Diagnostic Procedures.

Products